EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vaidyane Ayurved Laboratories EBITDA Margin % Related Terms
Vaidyane Ayurved Laboratories EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MADHAVBAUG vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a EBITDA Margin % of 14.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vaidyane Ayurved Laboratories and its competitors. This is 85% above median its historical median of 7.80. Over the past decade, Vaidyane Ayurved Laboratories' EBITDA Margin % has ranged from 3.61 to 16.64. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #376 out of 952 companies in the Drug Manufacturers industry, placing it in the top 39.5%.
Is Vaidyane Ayurved Laboratories' EBITDA Margin % too high?
Vaidyane Ayurved Laboratories' current EBITDA Margin % of 14.42% is 85% above median its 10-year median of 7.80. Over the past 10 years, this metric has ranged from a low of 3.61 to a high of 16.64. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Vaidyane Ayurved Laboratories' value of 14.42% is 15.6% above this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #376 out of 952 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #376 out of 952 companies for EBITDA Margin %. This puts Vaidyane Ayurved Laboratories in the upper half of its industry. The industry median EBITDA Margin % is 12.47. Vaidyane Ayurved Laboratories' value of 14.42% is 15.6% above this benchmark. Historically, Vaidyane Ayurved Laboratories' own EBITDA Margin % has ranged from 3.61 to 16.64 over the past decade. While the company's 10-year median is 7.80 vs. the industry median of 12.47, Vaidyane Ayurved Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current EBITDA Margin % of 14.42% is 15.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vaidyane Ayurved Laboratories and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current EBITDA Margin % is 14.42%, which is 85% above median its own 10-year median of 7.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹216.94, compared to a current price of ₹180.60 — trading 16.8% below its estimated fair value. The current EBITDA Margin % is 14.42%, which is 85% above median its 10-year median of 7.80 and 15.6% above the Drug Manufacturers industry median of 12.47. Vaidyane Ayurved Laboratories' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current EBITDA Margin % is 14.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹180.60 is trading 16.8% below its estimated GF Value™ of ₹216.94.
GuruFocus considers Vaidyane Ayurved Laboratories to be Modestly Undervalued.
Key valuation signals for NSE:MADHAVBAUG:
EBITDA Margin %: 14.42% (85% above median its 10-year median of 7.80)
GF Value™: ₹216.94 vs. price of ₹180.60 (16.8% below fair value)
Industry Position: 15.6% above the Drug Manufacturers median (#376 of 952)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidyane Ayurved Laboratories Business Description
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
81GF Score
Get the complete analysis for NSE:MADHAVBAUG
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
